Woolf Zoe, Stevenson Taylor J, Lee Kevin, Highet Blake, Macapagal Foliaki Jena, Ratiu Ramona, Rustenhoven Justin, Correia Jason, Schweder Patrick, Heppner Peter, Weinert Maria, Coppieters Natacha, Park Thomas, Montgomery Johanna, Smith Amy M, Dragunow Michael
Department of Pharmacology, The University of Auckland, Auckland, New Zealand.
Centre for Brain Research, The University of Auckland, Auckland, New Zealand.
Sci Rep. 2025 May 5;15(1):15621. doi: 10.1038/s41598-025-99867-z.
Microglia perform key homeostatic functions to protect the central nervous system (CNS). However, in many brain disorders their protective functions are abrogated, contributing to disease progression. Therefore, studies of microglial function are critical to developing treatments for brain disorders. Different in vitro microglia models have been established, including primary human and rodent cells, induced pluripotent stem cell (iPSC)-derived models, and immortalised cell lines. However, a direct comparative analysis of the phenotypic and functional characteristics of these models has not been undertaken. Accurate modelling of human microglia in vitro is critical for ensuring the translatability of results from the bench to the brain. Therefore, our study aimed to characterise and compare commonly utilised in vitro microglia models. We assessed four established microglia models: primary human microglia, human iPSC-derived microglia, the human microglial clone 3 (HMC3) cell line, and primary mouse microglia, with primary human brain pericytes acting as a negative control. Primary human microglia, iPSC-derived microglia, and mouse microglia stained positive for myeloid-cell markers (Iba1, CD45 and PU.1), while HMC3 cells only stained positive for mural-cell markers (PDGFRβ and NG2). Distinct secretomes were observed in all cell models in response to inflammatory treatment, with iPSC-derived microglia showing the most significant inflammatory secretions. Notably, nitric oxide was only secreted by mouse microglia. Although all cell types exhibited phagocytic capacity, primary human microglia and iPSC-derived microglia displayed significantly higher levels of phagocytosis. Overall, comparative analysis revealed notable differences between human microglia, iPSC-derived microglia, HMC3 cells and mouse microglia. Such differences should be considered when using these models to study human brain diseases. Experimental findings obtained from mouse models or cell lines should ultimately be cross validated to ensure the translatability of results to the human condition.
小胶质细胞执行关键的稳态功能以保护中枢神经系统(CNS)。然而,在许多脑部疾病中,它们的保护功能被废除,从而促进疾病进展。因此,小胶质细胞功能的研究对于开发脑部疾病的治疗方法至关重要。已经建立了不同的体外小胶质细胞模型,包括原代人细胞和啮齿动物细胞、诱导多能干细胞(iPSC)衍生模型以及永生化细胞系。然而,尚未对这些模型的表型和功能特征进行直接的比较分析。体外准确模拟人小胶质细胞对于确保从实验台到大脑的结果的可转化性至关重要。因此,我们的研究旨在表征和比较常用的体外小胶质细胞模型。我们评估了四种已建立的小胶质细胞模型:原代人小胶质细胞、人iPSC衍生的小胶质细胞、人小胶质细胞克隆3(HMC3)细胞系和原代小鼠小胶质细胞,以原代人脑海马周细胞作为阴性对照。原代人小胶质细胞、iPSC衍生的小胶质细胞和小鼠小胶质细胞对髓样细胞标志物(Iba1、CD45和PU.1)呈阳性染色,而HMC3细胞仅对壁细胞标志物(PDGFRβ和NG2)呈阳性染色。在所有细胞模型中,对炎症处理均观察到不同的分泌组,其中iPSC衍生的小胶质细胞显示出最显著的炎症分泌物。值得注意的是,一氧化氮仅由小鼠小胶质细胞分泌。虽然所有细胞类型都表现出吞噬能力,但原代人小胶质细胞和iPSC衍生的小胶质细胞表现出明显更高水平的吞噬作用。总体而言,比较分析揭示了人小胶质细胞、iPSC衍生的小胶质细胞、HMC3细胞和小鼠小胶质细胞之间的显著差异。在使用这些模型研究人类脑部疾病时应考虑这些差异。从小鼠模型或细胞系获得的实验结果最终应进行交叉验证,以确保结果对人类情况的可转化性。